Skip to main content

Table 1 Baseline characteristics of studies in MDR or XDRP.aeruginosa

From: Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author, Year Design Country Case/Exposure Control/Comparator Total N Age cases (Yr) Age control (Yr) Male cases (%) Male control (%)
Aloush, 2006 [12] CC, matched Israel MDR P. aeruginosa Patients with MDR P. aeruginosa 164 65 63 60 50
Bodro, 2015 [13] P, cohort Spain XDR P. aeruginosa Other pathogens 318 Median: 59 Median: 62 77.4 69.7
Cao, 2004 [14] CC, unmatched China MDR P. aeruginosa P.aeruginosa 112 60 50 59 58.8
Cilloniz, 2016 [15] P, cohort Spain MDR P. aeruginosa Non-MDR P. aeruginosa (not fully described) 68 72.7 71.1 90.9 78.3
Cobos-Trigueros, 2015 [16] P, cohort Spain MDR P. aeruginosa Susceptible or resistant P.aeruginosa and non-P.aeruginosa 850 NR NR NR NR
D’Agata (b), 2006 [17] CC, matched USA, Italy MDR P. aeruginosa Non-P.aeruginosa 302 58 62 62 50
Dalfino, 2011 [18] P, cohort NR MDR P. aeruginosa NR 251 63 63 65 61.3
Dantas, 2014 [19] R, cohort Brazil MDR P. aeruginosa Resistant or susceptible P. aeruginosa 120 51.5 (total) 51.5 (total) 63.3 (total) 63.3 (total)
Defez (a), 2004 [20] CC, matched France MDR P. aeruginosa, nosocomial Hospitalized, non-nosocomial MDRP. aeruginosa 320 73.2 67 56.25 52.5
Defez (b), 2004 [20] CC, unmatched France MDR P. aeruginosa Non MDR- P. aeruginosa (not described) 395 (155) 73.2 NR 56.25 56
Gomez-Zorilla, 2014 [21] P, cohort Spain MDR P. aeruginosa (MDR non-XDR and XDR) Non-MDR P. aeruginosa (not fully described) 112 65.3 (total) 65.3 (total) 69 (total) 69 (total)
Johnson, 2009 [22] R, cohort USA MDR P. aeruginosa Non-MDR P.aeruginosa (not described) 503 median: 59 (total) median: 59 (total) 57 (total) 57 (total)
Joo, 2011 [23] P, cohort South Korea MDR P. aeruginosa Resistant or susceptible P. aeruginosa 202 55 (total) 55 (total) 62.9 (total) 62.9 (total)
Liew, 2013 [24] CC, matched Singapore XDR P. aeruginosa Non-P. aeruginosa or other gram-negative 79 Median: 47 (total) NR 62 (total) NR
Lodise, 2007 [25] CC, unmatched USA MDR P. aeruginosa Non-MDR P.aeruginosa(not fully described)a 351 60.5 (total) 60.5 (total) 61.2 (total) 61.2 (total)
Micek, 2015 [26] R, cohort USA, France, Germany, Italy, Spain MDR P. aeruginosa Non-MDR P. aeruginosa (not fully described) 740 53.5 62.1 62.8 70.2
Montero (a), 2010 [27] CC, unmatched NR MDR P. aeruginosa Non-P. aeruginosa 1035 67.8 67.5 72.5 54.3
Montero (b), 2010 [27] CC, unmatched NR MDR P. aeruginosa Susceptible P.aeruginosa 877 67.8 69.1 72.5 59.4
Nakamura, 2013 [28] P, cohort Japan MDR P. aeruginosa Non MDR P.aeruginosa (not fully described)c 435 NR NR NR NR
Nseir, 2011 [29] P, cohort France MDR P. aeruginosa Non MDR P. aeruginosa (not fully described) 511 60 55 65 69
Ohmagari, 2005 [30] CC, unmatched USA Patients with cancer with MDR P. aeruginosa infection Patients with cancer with susceptible P. aeruginosa infection 54 51.8 60.3 50 58.3
Paramythiotou, 2004 [31] CC, matched France MDR P. aeruginosa Non-P. aeruginosa 68 59 61.5 65 65
Park, 2011 [32] CC, matched South Korea XDR P. aeruginosa Non-XDR P.aeruginosa (not fully described)b 99 65 56 79 46
Pena, 2009 [39] P, cohort Spain MDR P. aeruginosa CRPA 246 67 65 67 67
Pena (a), 2012 [33] R, cohort Spain XDR P. aeruginosa Susceptible P. aeruginosa 138 64.7 65.06 86 70.5
Pena (b), 2012 [33] R, cohort Spain Non-XDR MDR P. aeruginosa Susceptible P. aeruginosa 108 64.85 65.06 54 70.5
Samonis, 2014 [34] R, cohort Greece XDR P. aeruginosa Non-XDR P. aeruginosa (MDR and PDR and sensitive) 89 73 69 81.8 57.3
Tumbarello, 2011 [35] CC, unmatched Italy MDR P. aeruginosa Non-P. aeruginosa 252 62 63 57.5 57.5
Tuncer, 2012 [36] CC, unmatched Turkey MDR and XDR P. aeruginosa Non-MDR P.aeruginosa (not fully described) 120 58.6 58.2 54.1 49.4
Ustun, 2016 [37] CC, unmatched Turkey MDR P. aeruginosa Non-P. aeruginosa 225 29.8 37.9 58.7 65.3
Willmann, 2014 [38] CC, matched Germany XDR P. aeruginosa Non-XDR P. aeruginosa (not fully described) or non- P. aeruginosa 31 56 60 65 78.5
  1. CC Case-control, CRPA carbapenem-resistant P. aeruginosa, MDR multi-drug resistant, P Parallel, PDR Pan-Drug-Resistant, R Retrospective, XDR extremely drug-resistant, YR Year
  2. aLodise 2007: Non-MDR P.aeruginosa = ≥90% for only amikacin, cefepime, and piperacillin-tazobactam
  3. bPark,Y.S 2011:used random selection of controls
  4. cNakamura 2013:Non-MDR defines patients with P. aeruginosa other than the MDR phenotype on the same ward as those with the MDR phenotype within the same month
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us